A phase 2 study of CV301 in combination with Tecentriq® (atezolizumab) in patients with locally advanced or metastatic urothelial carcinoma (mUC), or bladder cancer
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Atezolizumab (Primary) ; CV 301 (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Therapeutic Use
- 08 Nov 2017 According to a Bavarian Nordic media release, this study is anticipated to initiate in the first half of 2018.
- 14 Mar 2017 New trial record
- 10 Mar 2017 According to a Bavarian Nordic media release, this study is anticipated to initiate around the end of 2017.